Eli Lilly (LLY) became the 10th U.S. company to tap $1 trillion in market cap and has outperformed most of its peers, particularly its biggest rival, Novo Nordisk (NVO). Rick Ducat shows just how massive Eli Lilly's run is and highlights how the "red-hot" stock will have to build up its bullish base. He sees a breather on the horizon for the stock. Rick later turns to the options front to show where traders are pricing shares to move.